CLINICAL TRIALS PROFILE FOR ERYC SPRINKLES
✉ Email this page to a colleague
All Clinical Trials for Eryc Sprinkles
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00136266 ↗ | Adherence With Iron Sprinkles Among High-Risk Infants | Completed | Centers for Disease Control and Prevention | Phase 3 | 2005-03-01 | Compared with iron drops, iron sprinkles supplied for 3 months to high-risk children beginning at age 5-7 months will increase adherence and reduce the rates of anemia and iron deficiency. |
| NCT00210574 ↗ | A Pilot Study of Topiramate in Childhood Absence Epilepsy | Completed | Ortho-McNeil Neurologics, Inc. | Phase 2 | 2005-03-01 | Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study. |
| NCT00210574 ↗ | A Pilot Study of Topiramate in Childhood Absence Epilepsy | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2005-03-01 | Limited data exist on the effectiveness of antiepileptic drugs for treatment of childhood absence epilepsy. Preliminary data suggest that topiramate may be an effective drug for this condition. The present study is designed to provide further evidence of the potential effectiveness of topiramate for childhood absence epilepsy, as well as preliminary information about a potential target dose for future study. |
| NCT00213161 ↗ | Using Iron Supplementation to Decrease Iron Deficiency Anemia in Infants and Young Children in India | Completed | The Hospital for Sick Children | N/A | 2004-08-01 | The purpose of this study is to determine the smallest dose of Sprinkles, a single-serving package of iron and other micronutrients, to treat infants with iron deficiency anemia in India. Results have implications for programs using Sprinkles worldwide because lower doses of iron may have fewer side effects. |
| NCT00233012 ↗ | A Study of the Pharmacokinetics, Safety and Tolerability of Topiramate in Infants (Age 1-24 Months) With Refractory Partial-onset Seizures | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2005-06-01 | The purpose of this study is to evaluate the pharmacokinetics safety and tolerability of topiramate in infants aged 1-24 months with refractory partial-onset seizures. Topiramate is an antiepileptic drug approved for use in adult and pediatric patients (aged 2 to 16 years) with refractory partial onset seizures (POS) with or without secondarily generalized seizures, primary generalized tonic clonic seizures, or Lennox-Gastaut syndrome (LGS). |
| NCT00379158 ↗ | Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana | Completed | NestlĂ© Foundation | Phase 4 | 2003-10-01 | 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles. |
| NCT00379158 ↗ | Comparison of the Efficacy and Acceptability of Three Types of Micronutrient Supplements in Ghana | Completed | United States Agency for International Development (USAID) | Phase 4 | 2003-10-01 | 1. At 12 mo of age, all three intervention groups will have significantly better iron and vitamin A status than the NI group. 2. Infants who receive the Foodlet or Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin B6, riboflavin and zinc status at 12 mo of age than the infants who receive the sprinkles containing iron and vitamin A only. 3. Infants who receive Nutributter will have significantly greater weight and length gains from 6 to 12 mo and higher indices of vitamin A and essential fatty acid (linoleic, alpha-linolenic and docosahexaenoic, DHA) status at 12 mo of age than the infants who receive the Foodlet or sprinkles. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Eryc Sprinkles
Condition Name
Clinical Trial Locations for Eryc Sprinkles
Trials by Country
Clinical Trial Progress for Eryc Sprinkles
Clinical Trial Phase
Clinical Trial Sponsors for Eryc Sprinkles
Sponsor Name
